| Old Articles: <Older 8831-8840 Newer> |
|---|
 |
Information Today
May 6, 2014 |
ProQuest Acquires Pi2 ProQuest announced its acquisition of the U.K.-based Pi2, which provides information and literature management to biopharmaceutical companies.   |
Pharmaceutical Executive
May 6, 2014
Adjei et al. |
Africa: The Lost Continent No More Driven by a rising GDP and calmer political and financial waters over the past decade, Africa's nascent healthcare sector is poised for a fresh surge in growth. |
Pharmaceutical Executive
May 6, 2014
Ben Comer |
The Brands of Yesteryear: Where Are They Now? We check back with previous Pharm Exec Brand of the Year winners like Januvia, Abbvie, and Gilenya to see how things are going. |
Pharmaceutical Executive
May 1, 2014
Ben Comer |
2014 Brand of the Year Brand of the Year recipients for 2014 are Copaxone, a mainstay treatment for multiple sclerosis, and KORLYM for diseases driven by excess production of the metabolic hormone, cortisol. We profile the journey of both drugs. |
Pharmaceutical Executive
May 1, 2014
Nadeem Rehmat |
Gravity Shift: Timely Lessons For Big Pharma MNCs can learn a lot from generic companies in their strategic approaches to emerging markets. |
Pharmaceutical Executive
May 1, 2014
Hansen & Melick |
Does Your Rigor Match Your Risk? Digital technology has changed the risk relationship between brands, HCPs, and patients; it's vital to get that technology working right the first time. |
Pharmaceutical Executive
May 1, 2014
Jill Wechsler |
Reimbursement Limits Threaten Drug Access High cost-sharing, narrow formularies create problems for pharma companies and patients. |
Pharmaceutical Executive
May 1, 2014
William Looney |
What's Real in Deals Recent deal making signals that the rehabilitation of big Pharma has entered a new phase aligned around a new strategic thesis: specialization and value differentiation are preferable to sheer bulk. |
Chemistry World
May 2, 2014
Phillip Broadwith |
Forest Labs buys Furiex for bowel drug Forest Laboratories has agreed to buy Furiex pharmaceuticals for $1.1 billion in cash, with a top-up of up to $360 million contingent on approval of Furiex's irritable bowel syndrome drug eluxadoline. |
Chemistry World
April 30, 2014
Emma Stoye |
New Zealand in legal highs U-turn Politicians in New Zealand have decided to ban designer drugs from sale in the country, reversing an earlier decision to approve low risk drugs while new laws are put in place. |
| <Older 8831-8840 Newer> Return to current articles. |
